Navigation Links
BioMS Medical to present at Sachs Associates Biotech in Europe Forum
Date:9/19/2008

the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
...d., Nov. 4 PharmAthene, Inc.,(NYSE Alternext US: ...ermeasures against biological and chemical threats...and Chief Executive Officer of PharmAthene,will pr...care Conference in,New York on Wednesday, November...s II Room (4th Floor) at The New York Palace Hotel...
...celand, November 4 deCODE,genetics (Nasdaq: DCGN ...aring before a Nasdaq Listing Qualifications Panel...asdaq Marketplace Rule 4450(b)(1)(A), which,requir...$50 million. On,October 31, 2008, deCODE received ... Market LLC indicating that the Company had not re...
...d., Nov. 4 Novavax, Inc. (Nasdaq:,NVAX) today ann...financial,results in a press release to be issued ... The Company will hold an investor conference call...stern Time on November 10,2008. The call will be h...icer Dr. Rahul Singhvi and other members of senior...
Other Biology Technology:deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 2deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 3deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 4Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call 2
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Ministerial Roundtable Discusses Future of Medical Tourism 62455 1Ministerial Roundtable Discusses Future of Medical Tourism 62455 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 1Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 2Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 3Oncolytics Biotech 28R 29 Inc Announces Exercise of Underwriters Over Allotment Option 15047 4Neil H Ekblom and Medical Malpractice Defense Team Join LeClairRyan 6686 1Neil H Ekblom and Medical Malpractice Defense Team Join LeClairRyan 6686 2Neil H Ekblom and Medical Malpractice Defense Team Join LeClairRyan 6686 3
...e isolated a new peptide antibiotic from the Ameri... many diseases in oysters. , The new antimicrobial...ect against bacteria in Crassostrea virginica, a s...ant economically to Atlantic and Gulf Coast fisher...disease-resistant oysters for aquaculture and fish...
...e Department of Energy,s Lawrence Berkeley Nationa...ct tens of thousands of high-quality images of bio...y and automatically, with accuracy approaching tha...thm, described as "particle picking by segmentatio...er of methods for determining biological structure...
...c. 4 as an advance online publication of the journ...have virtually no activity in a key part of the br...erving emotions. , Mirror neurons fire when a pers... she observes the same action performed by others....n matching system provides a neural mechanism by w...
Other Biology News:Picking particles faster than one at a time 2Picking particles faster than one at a time 3Picking particles faster than one at a time 4Picking particles faster than one at a time 5UCLA imaging study of children with autism finds broken mirror neuron system 2
Human Serum (All Male Donors) from Irvine Scientific
Human Serum Type AB from Irvine Scientific
Senescence Colorimetric Assay Kit from BioVision
Rabbit Anti-Human TARDBP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: